Otsuka Unveils Two-Year Kidney Function Data for VOYXACT in IgA Nephropathy
Event summary
- Otsuka to present two-year eGFR results from Phase 3 VISIONARY trial of VOYXACT at GlomCon Hawaii 2026 on August 3, 2026.
- Data supports rolling submission for traditional FDA approval after accelerated approval in November 2025.
- VOYXACT is the first-and-only U.S. FDA-approved selective APRIL inhibitor for IgA nephropathy.
- Key secondary endpoint evaluates annualized eGFR slope over two years to assess kidney function.
The big picture
Otsuka's presentation of two-year eGFR data for VOYXACT marks a critical step in solidifying its position as the first approved selective APRIL inhibitor for IgA nephropathy. The strategic focus on modifying disease progression through targeted therapy aligns with broader industry trends toward precision medicine in rare kidney diseases. Success here could expand Otsuka's footprint in nephrology, complementing its existing portfolio in neuroscience and immunology.
What we're watching
- Regulatory Pathway
- Whether the two-year eGFR data will secure traditional FDA approval following accelerated approval.
- Market Positioning
- How Otsuka positions VOYXACT against potential competitors in IgA nephropathy treatment.
- Long-Term Efficacy
- The pace at which additional long-term data from the open-label extension study emerges to support clinical benefit.
Related topics